Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Drople... Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits. Mehr anzeigen
Jury in Trademark Infringement Case Finds in Favor of ImprimisRx Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced a favorable jury verdict in the...
MELT-300 Demonstrates Statistically Superior Compared to Both Sublingual Midazolam (P=0.009) and Placebo (P<0.001) for Providing Successful Procedural Sedation Proportion of Patients Requiring...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences: Craig-Hallum 15th...
Third Quarter 2024 and Recent Selected Highlights: Revenues increased 44% from $34.3 million in the prior-year quarter to $49.3 million GAAP net loss of $(4.2) million Adjusted EBITDA of $8.8...
New Partnership with GoodRx to Lower Costs for Uninsured and Underinsured Patients Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced its first major market access wins in the 2025 Medicare Part D Prescription Drug Program. Starting...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the nationwide launch of a new digital patient access solution in collaboration with Asembia, a...
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 14, 2024 Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced...
Topline Readout Expected in Q4 2024 FDA Agrees to a MELT-300 Phase 3 Special Protocol Assessment Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative‑free...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.04 | 5.94752186589 | 34.3 | 36.66 | 32.4 | 382183 | 34.42215597 | CS |
| 4 | -1.63 | -4.29286278641 | 37.97 | 40.7 | 32.4 | 329427 | 35.49023156 | CS |
| 12 | -14.3299 | -28.2808926009 | 50.6699 | 59.23 | 32.4 | 503809 | 44.26450107 | CS |
| 26 | 15.31 | 72.8007608179 | 21.03 | 59.23 | 21.03 | 525239 | 40.07324203 | CS |
| 52 | 24.24 | 200.330578512 | 12.1 | 59.23 | 9.13 | 494282 | 27.62168806 | CS |
| 156 | 27.72 | 321.577726218 | 8.62 | 59.23 | 5.4 | 379095 | 20.4308553 | CS |
| 260 | 29.13 | 404.022191401 | 7.21 | 59.23 | 3.33 | 297450 | 17.29103342 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
